The discovery and characterization of ML218: A novel, centrally active T-Type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease

ACS Chemical Neuroscience

Volumn 2, Issue 12, 2011, Pages 730-742

  Xiang, Zixiu ^a   Thompson, Analisa D ^a   Brogan, John T ^b   Schulte, Michael L ^b   Melancon, Bruce J ^a,b   Mi, Debbie ^a   Lewis, L Michelle ^a   Zou, Bende ^b   Yang, Liya ^b   Morrison, Ryan ^a,b   Santomango, Tammy ^a   Byers, Frank ^a   Brewer, Katrina ^a   Aldrich, Jonathan S ^a,b   Yu, Haibo ^c   Dawson, Eric S ^a,b   Li, Min ^c,d   McManus, Owen ^c,d   Jones, Carrie K ^a   Daniels, J Scott ^a,b   Hopkins, Corey R ^a,b   Xie, Ximin Simon ^b   Conn, P Jeffrey ^a,b   Weaver, C David ^a,b   Lindsley, Craig W ^a,b   more..

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AfaSci Inc   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

electrophysiology; inhibitor; Parkinson's disease; T Type calcium channel

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; EFONIDIPINE; ETHOSUXIMIDE; FLUNARIZINE; HALOPERIDOL; MIBEFRADIL; ML 218; PIMOZIDE; UNCLASSIFIED DRUG; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BRAIN ELECTROPHYSIOLOGY; CATALEPSY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

RATTUS; RODENTIA;

EID: 84555194740     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn200090z     Document Type: Article

References (52)

1. Petegem, F. V. and Minor, D. L., Jr. (2006) The structural biology of voltage-gated calcium channel function and regulation Biochem. Soc. Trans. 34, 887-893
2. Huguenard, J. R. (1998) Low-voltage-activated (T-type) calcium-channel genes identified Trends Neurosci. 21, 451-452 (Pubitemid 28506132)
3. Ertel, E. A., Campbell, K. P., Harpold, M. M., Hofmann, F., Mori, Y., Perez-Reyes, E., Schwartz, A., Snutch, T. P., Tanabe, T., Birnbaumer, L., Tsien, R. W., and Catterall, W. A. (2005) Nomenclature of voltage-gated calcium channels Neuron 25, 533-535
4. Catterall, W. A., Perez-Reyes, E., Snutch, T. P., and Striessing, J. (2005) International Union of Pharmacology. XLVIII. Nomenclature and structure-function of voltage-gated calcium channels Pharmacol. Rev. 57, 411-425 (Pubitemid 43036432)
5. 2+ channels Annu. Rev. Cell Dev. Biol. 16, 521-555 (Pubitemid 32037516)
6. Carbone, E. and Lux, H. D. (1984) A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurons Nature 310, 501-502 (Pubitemid 14052412)
7. Lacinova, L. (2004) Pharmacology of recombinant low-voltage activated calcium channels Curr. Drug Targets: CNS Neurol. Disord. 3, 105-111 (Pubitemid 38854905)
8. Talley, E. M., Cribbs, L. L., Lee, J. H., Daud, A., Perez-Reyes, E., and Bayliss, D. A. (1999) Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels J. Neurosci. 19, 1895-1911 (Pubitemid 29133368)
9. Nelson, M. T., Todorovic, S. M., and Perez-Reyes, E. (2006) The role of T-type calcium channels in epilepsy and pain Curr. Pharm. Des. 12, 2189-2197 (Pubitemid 43891394)
10. Perez-Reyes, E. (2006) Molecular characterization of T-Type calcium channels Cell Calcium 40, 89-96 (Pubitemid 43942294)
11. 2+ channels as therapeutics in the nervous system Curr. Opin. Pharmacol. 8, 33-41
12. Contreas, D. (2006) The role of T-channels in the generatin of thalamocortical rythyms CNS Neurol. Disord.: Drug Targets 5, 571-585
13. Llinás, R. and Yarom, Y. (1981) Electrophysiology of mammalian inferior olivary neurones in vitro. Different types of voltage-dependent ionic conductances J. Physiol. 315, 549-67 (Pubitemid 11072016)
14. Wilms, H., Sievers, J., and Deuschl, G. (1999) Animal models of tremor Mov. Disord. 14, 557-71 (Pubitemid 30011448)
15. Miwa, H. (2007) Rodent models of tremor Cerebellum 6, 66-72 (Pubitemid 46410668)
16. Park, Y. G., Park, H. Y., Lee, C. J., Choi, S., Jo, S., and Choi, H. (2010) Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive Proc. Natl. Acad. Sci. U.S.A. 107, 10731-10736
17. Hassani, O. K., Mouroux, M., and Feger, J. (1999) Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus Neuroscience 72, 105-115 (Pubitemid 26092990)
18. Hammond, C., Beurrier, C., Garcia, L., and Bioulac, B. (2002) Physiological and pathological patterns in subthalamic neurons related to Parkinson's disease Neurophysiology 34, 96 (Pubitemid 36096937)
19. Miwa, H., Koh, J., Kajimoto, Y., and Kondo, T. (2011) Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats Pharmacol., Biochem. Behav. 97, 656-659
20. Morita, S., Miwa, H., and Kondo, T. (2005) Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol Parkinsonism Relat. Disord. 11, 101-103 (Pubitemid 40279150)
21. 2+ channel antagonist on thalamic relay and local circuit interneurons in a rat model of absence epilepsy Neuropharmacology 53, 431-446 (Pubitemid 47212254)
22. Leuranguer, V., Mangoni, M. E., and Nargeot, R. S. (2001) Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects J. Cardiovasc. Pharmacol. 37, 649-661 (Pubitemid 32480433)
23. Moosmang, S., Haider, N., Bruderl, B., Welling, A., and Hofmann, F. (2006) Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2 Circ. Res. 6, 105-110 (Pubitemid 43970209)
24. 2+ channels Cardiovasc. Drug Rev. 20, 81-92 (Pubitemid 34651324)
25. 2+ channel blockade by flunarizine in ventricular myocytes of the guinea-pig Eur. J. Pharmacol. 296, 189-197
26. Bancila, M., Copin, J. C., Daali, Y., Schatlo, B., Gasche, Y., and Bijlenga, P. (2011) Two structurally different T-type Ca 2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats Fundam. Clin. Pharmacol. 25, 469-478
27. Giordanetto, F., Knerr, L., and Walberg, A. (2011) T-type calcium channels inhibitors: a patent review Exp. Opin. Ther. Patents 21, 85-101
28. Shipe, W. D., Barrow, J. C., Yang, Z.-Q., Lindsley, C. W., Yang, F. V., Schlegel, K. S., Shu, Y., Rittle, K. E., Zrada, M. M., Bock, M. G., Hartman, G. D., Tang, C., Ballard, J. E., Kuo, Y., Adarayan, E. D., Prueksaritanont, Y., Uebele, V. N., Nuss, C. E., Connolly, T. M., Doran, S. M., Fox, S. V., Kraus, R. L., Marino, M. J., Graufelds, V. K., Vargas, H. M., Bunting, P. B., Hasbun-Manning, M., Evans, R. M., Koblan, K. S., and Renger, J. J. (2008) Design, synthesis and evaluation of novel 4-aminomethyl-4-fluoropiperidine as a T-Type Ca2+ antagonist J. Med. Chem. 51, 3692-3695 (Pubitemid 351956500)
29. Yang, Z.-Q., Barrow, J. C., Shipe, W. D., Schlegel, K. S., Shu, Y., Yang, F. V., Lindsley, C. W., Rittle, K. E., Bock, M. G., Hartman, G. D., Uebele, V. N., Nuss, C. E., Fox, S. V., Kraus, R. L., Doran, S. M., Connolly, T. M., Tang, C., Ballard, J. E., Kuo, Y., Adarayan, E. D., Prueksaritanont, Y., Zrada, M. M., Marino, M. J., DiLella, A. G., Reynolds, I. J., Vargas, H. M., Bunting, P. B., Woltman, M. M., Koblan, K. S., and Renger, J. J. (2008) Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels J. Med. Chem. 51, 6471-6477
30. Barrow, J. C., Lindsley, C. W., Shipe, W. D., Yang, Z., and Wisnoski, D. D. (2010) 4-Fluoro-Piperdine T-Type Calcium Channel Antagonists. WO 0216841.
31. Barrow, J. C., Lindsley, C. W., Shipe, W. D., and Yang, Z. (2010) 3-Fluoro-Piperdine T-Type Calcium Channel Antagonists. WO 0222387.
32. Renger, T. S., Yang, Z. Q., Schlegel, K. S., Shu, Y., Mattern, C., Cube, R., Rittle, K. E., McGaughey, G. B., Hartman, G. D., Tang, C., Ballard, J., Kuo, Y., Prueksaritanont, T., Nuss, C. E., Doran, S. M., Fox, S. V., Garson, S. L., Yuxing, L., Kraus, R. L., Uebele, V. N., Renger, J. J., and Barrow, J. C. (2011) Pyridyl amides as potent inhibitors of T-type calcium channels Bioorg. Med. Chem. Lett. 21, 1692-1696
33. Schlegel, K. S., Yang, Z. Q., Renger, T. S., Shu, Y., Cube, R., Rittle, K. E., Bondiskey, P., Bock, M. G., Hartman, G. D., Tang, C., Ballard, J., Kuo, Y., Prueksaritanont, T., Nuss, C. E., Doran, S. M., Fox, S. V., Garson, S. L., Yuxing, L., Kraus, R. L., Uebele, V. N., Renger, J. J., and Barrow, J. C. (2010) Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists Bioorg. Med. Chem. Lett. 20, 5147-5152
34. Dreyfus, F. M., Tscherter, A., Errington, A. C., Renger, J. J., Shin, H.-S., Uebele, V. N., Crunelli, V., Lambert, R. C., and Leresche, N. (2010) Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of IT window J. Neurosci. 30, 99-109
35. Smith, E. M., Sorota, S., Kim, H. M., McKittrick, B. A., Nechuta, T. L., Bennett, C., Knuston, C., Burnett, D. A., Kieselgof, J., Tan, Z., Rindgen, D., Bridal, T., Zhou, X., Jia, Y.-P., Dong, Z., Mullins, D., Zhang, X., Priestly, T., Correll, C. C., Tulshian, D., Czarniecki, M., and Greenlee, W. J. (2010) T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis Bioorg. Med. Chem. Lett. 20, 4602-4606
36. Choi, Y.-H., Baek, D. J., Lee, J. K., Pae, A. N., Cho, Y. S., and Min, S.-J. (2011) Facile synthesis and biological evaluation of 3,3-diphenylpropanoyl piperazines as T-type calcium channel blockers Bioorg. Med. Chem. Lett. 21, 215-219
37. Hangeland, J. J., Cheney, D. L., Friends, T. J., Swartz, S., Levesque, P. C., Rich, A. J., Sun, L., Bridal, T. R., Adam, L. P., Normandin, D. E., Murugesan, N., and Ewing, W. R. (2008) Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core Bioorg. Med. Chem. Lett. 18, 474-478
38. Gu, S. J., Lee, J. K., Pae, A. N., Chung, H. J., Rhim, H., Han, S. Y., Min, S.-J., and Cho, Y. S. (2010) Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers Bioorg. Med. Chem. Lett. 20, 2705-2708
39. Fritch, P. C. and Krajewski, J. (2010) Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists Bioorg. Med. Chem. Lett. 20, 6375-6378
40. Lee, J. E., Koh, H. Y., Seo, S. H., Baek, Y. Y., Rhim, H., Cho, Y. S., and Pae, A. N. (2010) Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers Bioorg. Med. Chem. Lett. 20, 4219-4222
41. For information on the MLSCN and MLPCN, see http://mli.nih.gov/mli/mlpcn/ .
42. Xie, X., Van Duesen, A. L., Vitko, I., Babu, D. A., Davies, L. A., Huynh, N., Cheng, H., Yang, N., Barrett, P. Q., and Perez-Reyes, E. (2007) Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches Assay Drug Dev. Technol. 5, 191-203 (Pubitemid 46684907)
43. For information on the MLPCN, see the MLPCN database Pubchem (open access): http://pubchem.ncbi.nlm.nih.gov/.
44. Jain, A. M. (2000) Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition J. Comput.-Aided Drug Des. 14, 199-213
45. For information on the Ricerca Lead Profiling Screen, see www.ricerca.com.
46. 5: Discovery of a new tool compound with activity in mouse models of anxiety and addiction ACS Chem. Neurosci. 2, 471-482
47. ir2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR and pharmacological characterization of ML133 ACS Chem. Biol. 6, 845-856
48. 1 positive allosteric modulator (PAM): the development of ML169, an MLPCN Probe Bioorg. Med. Chem. Lett. 21, 2697-2701
49. 4) with CNS Exposure in Rats J. Med. Chem. 54, 1106-1110
50. Williams, R., Zhou, Y., Niswender, C. M., Luo, Q., Conn, P. J., Lindsley, C. W., and Hopkins, C. R. (2010) Re-exploration of the PHCCC scaffold: Discovery of improved positive allosteric modulators of mGluR4 ACS Chem. Neurosci. 1, 411-419
51. Niswender, C. M., Myers-Johnson, K. A., Weaver, C. D., Jones, C. K., Luo, Q., Rodriguez, A. L., Marlo, J. E., de Paulis, T., Thompson, A., Days, E., Nalywajko, N. T., Austin, C., Williams, M., Ayala, J. E., Williams, R., Lindsley, C. W., and Conn, P. J. (2008) Discovery, characterization and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 Mol. Pharmacol. 74, 1345-1358
52. 2A receptor antagonists with in vivo efficacy J. Med. Chem. 51, 400-406 (Pubitemid 351252268)